摘要
目的 检测CD90及端粒酶逆转录酶（hTERT）在原发性肝癌中的表达，研究其蛋白产物在原发性肝癌发生、发展过程中的表达特点及相互关系。方法 应用免疫组化S-P法检测36例原发性肝癌中CD90、hTERT的表达，并以同期20例正常肝组织作对照。结果 肝癌组织中CD90、hTERT基因蛋白产物阳性表达率（分别为63．9％和47．2％）显著高于良性对照组（CD90、hTERT均阴性）；CD90、hTERT蛋白在UICC临床分期Ⅲ～Ⅳ期肝癌患者（分别为79．1％和62．5％）明显高于Ⅰ～Ⅱ期患者（分别为33．3％和16．6％）；CD90、hTERT两者呈正相关；CD90、hTERT阳性患者生存率（术后中位生存时间分别为85d和76d）明显低于CD90、hTERT阴性患者（术后中位生存时间分别为505d和463d），log秩检验显示生存率差异均有统计学意义。结论 CD90可能与肝癌的发生、发展相关，有望成为判断患者预后的指标之一。
Objective To study the expressions of CD90 and hTERT in hepatocellular carcino- ma （HCC）, and their relationships to progression of tumor. Methods The expressions of CD90 and hTERT in hepatocellular carcinoma were detected by S-P immunohistochemical staining. Twenty patients with hemangiomas of liver were used as control. Results Compared with the control group, the positive rates of CD90 and hTERT in HCC were significantly higher （63.9% and 47.2% vs 0% and 0%）. The positive rates of CD90 and hTERT were significantly higher in patients with tumors at UICC Ⅲ-Ⅳ stage than at UICC stage Ⅰ-Ⅱ （79.1% and 62.5% vs 33.3% and 16.6%）. The CD90 expression correlated with hTERT positively. There were significant differences in survival between patients with CD90＋ and CD90- or hTERT＋ and hTERT-. The median postoperative survivals for patients with CD90＋ and hTERT＋, CD90- and hTERT- were 85 d and 76 d, 505 d and 463 d, respectively. Conclusions CD90 expression correlated positively with progression of HCC. It has the potential to serve as a prognostic marker for HCC.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2012年第1期37-39,共3页
Chinese Journal of Hepatobiliary Surgery
基金
江苏省医学重点人才（RC201i090）
江苏省自然科学基金（SBK201120268）
国家自然基金专项基金项目（61141013）
